ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Biology and Pathology of Bone and Joint Poster I

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 59
Abaloparatide, a Novel PTHrP Analog, Increased Bone Mass and Density at Cortical and Trabecular Sites in an Orchiectomized Rat Model of Male Osteoporosis
9:00AM-11:00AM
Abstract Number: 57
Accelerated Development of Aging-Associated and Instability-Induced Osteoarthritis in 12/15-Lipoxygenase Deficient Mice
9:00AM-11:00AM
Abstract Number: 56
Baicalein, a Plant-Derived Small Molecule, Activate Nrf2/Autophagy Signaling Axis Via MEK1/2-ERK1/2-Elk1 Pathway to Suppress the Expression of IL-6 in Human Osteoarthritis Chondrocytes
9:00AM-11:00AM
Abstract Number: 58
Cartilage-like Tissue Generation By 3D-Bioprinting of Induced Pluripotent Stem Cells
9:00AM-11:00AM
Abstract Number: 47
Claudin-11 Regulates Bone Homeostasis Via Bidirectional EphB4-EphrinB2 Signaling
9:00AM-11:00AM
Abstract Number: 62
Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis
9:00AM-11:00AM
Abstract Number: 49
G Protein-Coupled Receptor Kinase 3 Modulates Mesenchymal Stem Cell Proliferation and Differentiation through Sphingosine-1-Phosphate Receptor Regulation
9:00AM-11:00AM
Abstract Number: 66
Genome-Wide DNA Methylation Profiling of OA PBMCs Reveals Slowed Epigenetic Aging Among Rapid Radiographic Progressors: Data from the Osteoarthritis Initiative (OAI)
9:00AM-11:00AM
Abstract Number: 52
In Vivo Effect of Opticin Deficiency in a Surgically Induced Mouse Model of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 51
Irisin Ameliorates Infrapatellar Adiposity in Knee Osteoarthritis Pathogenesis By Orchestrating Adipokine Signaling
9:00AM-11:00AM
Abstract Number: 60
Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy
9:00AM-11:00AM
Abstract Number: 54
Maintaining Angiogenesis Prevents Glucocorticoid Induced Osteonecrosis
9:00AM-11:00AM
Abstract Number: 63
MiR-146a a Key Player in Bone Metabolism
9:00AM-11:00AM
Abstract Number: 48
Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality
9:00AM-11:00AM
Abstract Number: 55
Nrf2 Inhibits Apoptosis and Suppresses Oxidative Stress By Activating NOX4/ERK1/2/ELK1 Signaling Axis in Human Chondrocytes
9:00AM-11:00AM
Abstract Number: 53
Poly-γ-Glutamic Acid Inhibits RANKL- Induced Osteoclast Differentiation and Prevents Bone Destruction in Rheumatoid Arthritis: Human and CIA Mouse Model
9:00AM-11:00AM
Abstract Number: 50
Quality Controls Monitoring As Indicator of Stability in Bone and Cartilage Turnover Markers for Clinical Trials
9:00AM-11:00AM
Abstract Number: 65
RA-Associated Antibodies Targeting Post Translational Modification Have Different Osteoclastogenetic Potential
9:00AM-11:00AM
Abstract Number: 61
Resolution of Systemic Joint Inflammatory Processes and Regeneration of Existing Bone Damage upon TNF Blockade As Monitored By In Vivo Multimodal PET-CT Imaging in Progressed Experimental Arthritis
9:00AM-11:00AM
Abstract Number: 68
Tankyrase/Wnt Inhibitor Upregulates Osteoclastogenesis and Osteoblastogenesis Via SH3BP2
9:00AM-11:00AM
Abstract Number: 64
The Effect of Adenosine A2A Receptor Stimulation on Mitochondrial Metabolism in the Pathogenesis and Treatment of Osteoarthritis
9:00AM-11:00AM
Abstract Number: 69
The Effect of Myostatin Inhibition on Bone Loss in Murine Osteoporosis Models
9:00AM-11:00AM
Abstract Number: 67
The Oxygen Sensor PHD1 Is an Indispensable Regulator of Arthritis Development

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology